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Schistosomiasis is a major public health problem. More than
200 million people in 74 countries currently have the disease;
120 million of them have symptoms while 20 million have
severe illness [1]. Traditional diagnosis of Schistosoma mansoni
infection involves direct microscopic detection of eggs in feces.
However, such a diagnostic approach has some limitations
that include a lack of sensitivity as the extent of egg shedding
may ﬂuctuate widely, and as many as three specimens may be
required in some patients. The use of some stool concentrationtechniques may increase the diagnostic yield [2]. However, it
seems that the sensitivity of parasitological methods dimin-
ishes when prevalence and intensity of infection are low, mak-
ing these methods less appropriate for low-endemic areas and
in post treatment situations [3]. Alternatively, the immunolog-
ical detection of schistosome infection may be used. Such tech-
niques may be useful but there are still problems with their
sensitivity and speciﬁcity [4]. Polymerase Chain Reaction
(PCR) based diagnosis of S. mansoni is a relatively new
approach that is used for the detection of the parasite DNA
in serum or fecal samples. The ampliﬁcation reaction is capa-
ble of detecting as little as 1 fg of DNA, highly speciﬁc and
is 10 times more sensitive than the Kato-Katz technique [5,6].
Praziquantel (PZQ) is considered the drug of choice for
treatment of schistosome infections and a major advance in
the treatment of most trematode and cestode infections.
This pharmaceutical product is the ﬁrst anthelminthic drug
to fulﬁll the World Health Organization’s requirements for
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infections [7]. However, a relative resistance of the larval stages
of S. mansoni to the drug is well documented [8]. Also, PZQ
has been in use for more than 25 years [9], and concern is
increasing that resistance has emerged in human parasites
[10]. The situation is further complicated because the two other
drugs for treatment of schistosomiasis either are no longer
available (metrifonate) or are not effective against all species
of schistosomes (metrifonate and oxamniquine) [11].
In 2001, a new antischistosomal drug, Mirazid (the oleo-
resin extract from myrrh of Comiphora molmol tree, family:
Burseraceae) was introduced into the Egyptian market in the
form of gelatinous capsules produced by Pharco Pharmaceuti-
cal Company (Alexandria, Egypt). The extensive advertising
efforts have encouraged physicians in private clinics to use
Mirazid although it is not used by the Ministry of Health
and Population (MoHP) in the national schistosomiasis con-
trol programs [12]. The chemistry of myrrh is not fully eluci-
dated [13]. Reports on the drug anti-schistosomal effect in
human or experimental animals are controversial [12].
The present study is a laboratory trial that aims at using
and evaluating the conventional PCR technique for studying
the schistosomicidal effect of Mirazid in the murine model,
and comparing the results of the molecular study with the par-
asitological results (ova and worm count).
Material and methods
The study was carried out on male Swiss albino mice of match-
ing age (8 weeks) and weight (20 ± 2 g). Animals were ob-
tained from Theodor Bilharz Research Institute (TBRI),
Cairo, Egypt. The mice were kept in a controlled environment
and maintained on water and stock commercial pellet diet ad
libitum.
The mice were divided into three groups of ten animals
each.
Group 1
Normal healthy control animals.
Group 2
S. mansoni infected mice sacriﬁced after 45 days of infection to
avoid mortality of untreated mice.
Group 3
Mice treated with 600 mg Mirazid/kg body weight for ﬁve
consecutive days on empty stomach after 45 days of the S.
mansoni infection. Animals of this group were then left for
27 days after the last treatment and sacriﬁced.
Each mouse was infected with 100 cercariae of TBRI labo-
ratory strain of S. mansoni using the tail immersion technique
[14].
Worm count
Adult S. mansoni worms were recovered from the hepatic por-
tal system and the liver by the perfusion technique as described
by Smithers and Terry, and the number of worms was then
counted [15].Counting of eggs in stool
Starting from the 28th day after infection, the animals were
separated and feces passed by each animal were collected indi-
vidually and examined by a modiﬁed Kato-Katz technique. A
stool pellet was weighted, processed and examined by the
Kato-Katz technique. The number of eggs per gram (epg) stool
was calculated [16].
Extraction of DNA from stool
Extraction of DNA from stool samples was done using QIA-
amp DNA stool mini Kit (QIAGEN, GmbH, Hilden,
Germany).
Pcr
The PCR was done using a forward primer (50-GAT CTG
AAT CCG ACC AAC CG-30) and reverse primer (50-ATA
TTA ACG CCC ACG CTC TC-30) that were designed to am-
plify the 121-bp tandem repeat DNA sequence of S. mansoni.
Brieﬂy, for a 25 lL ﬁnal volume of PCR mixture, 5 lL of
DNA extract was used as template, 12.5 lL 2X PCR Master
Mix (0.05 u/lL Taq DNA Polymerase, reaction buffer,
4 mM MgCl2, 0.4 mM of each dNTPs), 1.5 lL of each primer
and ﬁnally 4.5 lL of molecular biology grade water. The
ampliﬁcation reaction was carried out for 35 cycles, with each
cycle consisting of a denaturation step at 95 C for 40 s, an
annealing step at 60 C for 30 s and an extension step at
72 C for 1 min. The ﬁrst cycle had an extended denaturation
step for 5 min and the reaction was ended with an extension
step at 72 C for 5 min. Ampliﬁed PCR products were ana-
lyzed by electrophoresis in 2.5% agarose gels and detected
by staining with ethidium bromide [5].
Statistical analysis
All data were expressed as Mean ± SD. Statistical signiﬁcance
was determined by one way analysis of variance (ANOVA)
accompanied by post hoc. The test was run on an IBM com-
patible PC using SPSS for windows statistical package
(Version 17; SPSS Inc., Chicago, IL).Results
The coproscopic examination of the two infected mice groups
by the Kato-Katz technique revealed that all mice were passing
S. mansoni eggs on the 45th day after infection. On the treated
group, after treatment till perfusion of mice there was a reduc-
tion in egg count, which decreased from 236 ± 166.5 epg on
the 45th day after infection to 7 ± 14.9 epg on the 77th day
(Fig. 1). On that day 8 out of 10 mice (80%) were diagnosed
negative by stool examination.
As regards the number of S. mansoni worms recovered from
sacriﬁced mice of the infected groups (Table 1), the untreated
group showed a higher number of worms as it was 29.3 ± 10.8
worms on the 45th day after infection, while the Mirazid trea-
ted group showed 9 ± 6 worms on the 77th day after infection.
This may indicate that there was a reduction of 69.3% in the
Mirazid treated group compared with the infected untreated
group. The difference in worm count between the two groups
Fig. 1 Mean egg count in stool samples (epg) of the Mirazid treated mice before and after treatment.
Table 1 Number of S. mansoni worms recovered from sacriﬁced mice of the infected groups.
Free male
Mean ± SD
(range)
Free female
Mean ± SD
(range)
Couple
Mean ± SD
(range)
Total
Mean ± SD
(range)
Worm reduction after
treatment (p-value of T-
test)
Untreated
group
7.3 ± 2 (4–10) 3.8 ± 1.5 (2–7) 9.1 ± 4.1
(4–17)
29.3 ± 10.8
(14–48)
–
Mirazid
treated group
2.6 ± 1.5 (1–5) 1.1 ± 1.0 (0–3) 3.0 ± 1.9 (1–7) 9.0 ± 6.0
(3–22)
69.3% (0.001)
Effect of Mirazid on Schistosoma mansoni 565was signiﬁcant. None of the treated mice showed complete
cure as worms were recovered from all the treated mice, and
at least one worm couple was recovered.
Concerning the results of using the PCR for detection of S.
mansoni speciﬁc DNA sequences in murine fecal samples of the
infected control group (Fig. 2A), all the fecal samples showed
positive results by using feces from the 45th day after infection.
On the other hand, all the fecal samples of the uninfected con-
trol group showed negative results (Fig. 2B). Regarding the
results of the Mirazid treated group (Fig. 2C), six fecal sam-
ples (60%) showed positive results for feces from the 77th day
after infection. Interestingly, the four mice diagnosed negative
by PCR were among the eight mice diagnosed negative by the
microscopic technique.
Discussion
One of the main requirements for diagnosing S. mansoni is the
development of a more sensitive assay. Consistent diagnosis of
the disease still depends on the parasitological demonstration
of the S. mansoni eggs in fecal samples, which is well accom-
plished by the Kato-Katz thick smears. Unfortunately, it seems
that the technique sensitivity is less appropriate in low intensity
conditions such as: low endemic areas, post-treatment, and for
determination of incidence [17]. Thus, a more sensitive ap-
proach would be of great value in such situations. For studying
of the schistosomicidal effect of Mirazid in the murine model
during the present work, in addition to the parasitological tech-
niques including Kato-Katz thick smears and worm count, a
PCR technique described by others was used [5,6]. According
to the Kato-Katz results, Mirazid succeeded to reduce the
S. mansoni egg count in murine feces and gave a cure rate of80%. By considering the results of the worm detection as the
gold standard for judging the cure of mice after treatment
(Table 1), it was found that although there was a signiﬁcant
reduction in worm count in the treated group none of the mice
was completely cured. By using the qualitative PCR technique
there was reduction in the number of the positive samples after
treatment and a cure rate amounted 40% (Fig. 2C). This may
indicate that the qualitative PCR technique is more sensitive
than the Kato-Katz thick smears. Although at least worm cou-
ple was present in the treated mice, egg deposition was not con-
ﬁrmed and negative PCR in the mice may denote absence or
very few eggs. Although, this is the ﬁrst report of usage of this
technique in diagnosis of murine S. mansoni, the present results
are supported by previous work of others who reported a
higher sensitivity of this PCR technique compared with the
Kato-Katz thick smears for detection of the S. mansoni DNA
in human fecal samples [18]. It is to be mentioned here that
the results of the present study should be interpreted with
caution because of the limited number of mice included in each
group.
The used PCR primers were designed by Pontes et al. [5,6]
to amplify a species speciﬁc highly repeated 121 bp sequence of
S. mansoni DNA that comprises about 10% of the parasite
genome. It was estimated that each S. mansoni cell have about
600,000 copies of this tandem repeat DNA sequence [5,6]. The
high sensitivity of the approach enabled the detection of the
parasite DNA in 2.16 epg of feces, which makes this technique
10 times more sensitive than the Kato-Katz examination. A
detection limit of 1 fg of S. mansoni DNA was determined
when pure DNA was used as PCR template [19].
There is a great debate about the efﬁcacy and even effective-
ness of myrrh in the treatment of S. mansoni, both in labora-
Fig. 2 Results of the PCR for murine fecal samples of the infected control [A], uninfected control [B] and Mirazid treated [C] groups
(M: molecular weight marker, lanes 1–10: samples).
566 W.M. Lotfy et al.tory and clinical settings. Badria et al. [20] reported the efﬁcacy
of myrrh in mice experimentally infected with S. mansoni. The
oral administration of myrrh extract at 250 and 500 mg/kg
body weight induced signiﬁcant reductions in worm burdens,
increased hepatic shift of worms and progressive reductions
in the percentages of immature eggs deposited in the intestinal
wall [20]. Massoud et al. [21] compared the efﬁcacy of myrrh
extract on different developmental stages of S. mansoni in
experimentally infected mice. They reported that myrrh extract
in a dose of 500 mg/kg body weight daily for ﬁve consecutive
days resulted in a valuable schistosomicidal effect which was
more evident in groups in which the drug was administered
on 21st as well as on 45th days post infection [21]. However,
other experiments negated the possibility of myrrh efﬁcacy in
the treatment of experimental schistosomiasis. The most strik-
ing results on the lack of therapeutic efﬁcacy of myrrh against
S. mansoni infected animals were obtained in a multicentre
investigation conducted by Botros et al. [22]. Different deriva-
tives of the myrrh resin, including the commercial preparation,
Mirazid, were tested using different doses against different
strains. The worm reduction rates in mice infected with the
Egyptian (CD) strain were negligible. High doses of Mirazid
solution were toxic for mice infected with the Puerto Rican
(Mill Hill) strain of S. mansoni while lower doses induced mod-
est or no worm reductions. In addition, no antischistosomal
activity was observed in mice and hamsters infected with the
Puerto Rican (NMRI) and Brazilian (LE) strains of S. mansonitreated with different concentrations of the crude extract of
myrrh [22].Conclusion
The used PCR technique was more sensitive than the
Kato-Katz thick smears in post-treatment diagnosis of murine
S. mansoni infection. Mirazid showed some schistosomicidal
effects against murine S. mansoni infection. However, it was
not efﬁcient enough to cure any of the studied mice. Thus,
we believe that the re-evaluation of myrrh as a human schist-
osomicidal drug is a must because of its recommendation by
some Egyptian physicians motivated by its natural origin.References
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